These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2111246)

  • 41. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.
    Pisani F; Fazio A; Oteri G; Spina E; Perucca E; Bertilsson L
    Br J Clin Pharmacol; 1988 May; 25(5):611-3. PubMed ID: 3136790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Valproic Acid and Its Amidic Derivatives as New Antivirals against Alphaherpesviruses.
    Andreu S; Ripa I; Bello-Morales R; López-Guerrero JA
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33256172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy.
    Barel S; Yagen B; Schurig V; Soback S; Pisani F; Perucca E; Bialer M
    Clin Pharmacol Ther; 1997 Apr; 61(4):442-9. PubMed ID: 9129561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid.
    Pessah N; Kaufmann D; Yagen B; Hen N; Wlodarczyk B; Finnell RH; Bialer M
    Epilepsia; 2010 Oct; 51(10):1944-53. PubMed ID: 20738383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
    Eikel D; Hoffmann K; Zoll K; Lampen A; Nau H
    Drug Metab Dispos; 2006 Apr; 34(4):612-20. PubMed ID: 16415118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative.
    Shimshoni JA; Yagen B; Wlodarczyk B; Finnell RH; Schurig V; Bialer M
    Epilepsia; 2010 Mar; 51(3):323-32. PubMed ID: 19674061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of valproic acid in patients with bipolar disorder.
    Vasudev K; Das S; Goswami U; Tayal G
    J Psychopharmacol; 2001 Sep; 15(3):187-90. PubMed ID: 11565626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
    Addison RS; Parker-Scott SL; Eadie MJ; Hooper WD; Dickinson RG
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):715-21. PubMed ID: 11214782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats.
    Bar-Klein G; Swissa E; Kamintsky L; Shekh-Ahmad T; Saar-Ashkenazy R; Hubary Y; Shrot S; Stetlander L; Eisenkraft A; Friedman A; Bialer M
    Epilepsia; 2014 Dec; 55(12):1953-8. PubMed ID: 25377630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
    Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.
    Ragueneau-Majlessi I; Levy RH; Brodie M; Smith D; Shah J; Grundy JS
    Clin Pharmacokinet; 2005; 44(5):517-23. PubMed ID: 15871637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
    Tang W; Abbott FS
    Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.
    Kerr BM; Rettie AE; Eddy AC; Loiseau P; Guyot M; Wilensky AJ; Levy RH
    Clin Pharmacol Ther; 1989 Jul; 46(1):82-93. PubMed ID: 2501059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus.
    Mawasi H; Bibi D; Shekh-Ahmad T; Shaul C; Blotnik S; Bialer M
    Mol Pharm; 2016 Jul; 13(7):2492-6. PubMed ID: 27218460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy.
    Gidal BE; Sheth R; Parnell J; Maloney K; Sale M
    Epilepsy Res; 2003 Dec; 57(2-3):85-93. PubMed ID: 15013050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
    Coupez R; Nicolas JM; Browne TR
    Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of valproic acid in the elderly.
    Perucca E; Grimaldi R; Gatti G; Pirracchio S; Crema F; Frigo GM
    Br J Clin Pharmacol; 1984 Jun; 17(6):665-9. PubMed ID: 6430313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.